Oral bioavailability of desloratadine is unaffected by food

Clinical Pharmacokinetics

Volumn 41, Issue SUPPL. 1, 2002, Pages 7-12

  Gupta, S ^a   Banfield, C ^a   Affrime, M ^a   Marbury, T ^b   Padhi, D ^a   Glue, P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036073476     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241001-00002     Document Type: Article

References (9)

1. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH
2. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring
3. 1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects
4. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons
5. A comparison of the two one-sided test procedure and the power approach for assessing the bioequivalence of average bioavailability
6. Desloratadine demonstrates dose proportionality in healthy adults after single doses